Roche announced plans to build what it calls pharma's largest AI supercomputer in partnership with Nvidia, just weeks after Eli Lilly unveiled its own system that executives dubbed the industry's most powerful. The Swiss drugmaker is positioning the project as an "AI factory" designed to accelerate drug discovery and development processes.
The announcement comes as pharmaceutical companies increasingly invest in artificial intelligence infrastructure to streamline research and reduce development timelines. Eli Lilly recently celebrated the launch of its supercomputer, marking a significant milestone in the industry's AI arms race.
Specific technical details about Roche's planned system, including computational capacity and timeline, were not disclosed in the initial announcement. The partnership with Nvidia suggests the system will leverage the chip maker's specialized AI processors that have become standard in high-performance computing applications.
The initiative reflects broader industry trends toward AI-powered drug discovery, as companies seek to improve success rates and reduce the traditional decades-long development process. The competition between major pharmaceutical companies to build superior AI infrastructure could accelerate innovation across the sector.